UY29128A1 - Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos - Google Patents

Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos

Info

Publication number
UY29128A1
UY29128A1 UY29128A UY29128A UY29128A1 UY 29128 A1 UY29128 A1 UY 29128A1 UY 29128 A UY29128 A UY 29128A UY 29128 A UY29128 A UY 29128A UY 29128 A1 UY29128 A1 UY 29128A1
Authority
UY
Uruguay
Prior art keywords
methods
compositions
derived
epithopes
proteins derived
Prior art date
Application number
UY29128A
Other languages
English (en)
Inventor
Jacqueline Benson
Mark Cunningham
Jeffrey Luo
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of UY29128A1 publication Critical patent/UY29128A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una proteína derivada de Ig humana, específica de anti-IL-23, ácidos nucleicos aislados, que codifican por lo menos una proteina derivada de Ig anti-IL-23, vectores, células huésped, plantas o animales transgénicos, y los métodos para preparar y usar los mismos, que son útiles como composiciones, métodos y dispositivos terapéuticos y de diagnóstico. La proteína derivada de Ig anti-IL-23 se une preferiblemente a uno o más de los epitopes Seg1, Seg2, y Seg3 de la subunidad p40 de IL-23.
UY29128A 2004-09-24 2005-09-23 Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos UY29128A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61286604P 2004-09-24 2004-09-24
US61683204P 2004-10-07 2004-10-07

Publications (1)

Publication Number Publication Date
UY29128A1 true UY29128A1 (es) 2005-11-30

Family

ID=36119430

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29128A UY29128A1 (es) 2004-09-24 2005-09-23 Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos

Country Status (7)

Country Link
US (2) US7252971B2 (es)
AR (1) AR051444A1 (es)
MY (1) MY141215A (es)
PE (1) PE20060694A1 (es)
TW (1) TWI370136B (es)
UY (1) UY29128A1 (es)
WO (1) WO2006036745A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
CA2501786C (en) * 2002-10-30 2015-02-17 Genentech, Inc. Inhibition of il-17 production
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100021455A1 (en) * 2004-12-08 2010-01-28 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
CA2613818C (en) * 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
SG165322A1 (en) 2005-08-31 2010-10-28 Schering Corp Engineered anti-il-23 antibodies
CN101296706B (zh) 2005-09-01 2011-11-30 先灵公司 Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途
US10716749B2 (en) * 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
WO2007147019A2 (en) * 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
US20100055700A1 (en) * 2007-02-28 2010-03-04 Cedars-Sinai Medical Center Role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
WO2008106131A2 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2008143892A1 (en) * 2007-05-18 2008-11-27 New York University Method of treating tuberculosis with interferons
US9305137B1 (en) 2007-05-18 2016-04-05 Cedars-Sinai Medical Center Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach
US9421356B2 (en) * 2007-08-28 2016-08-23 Teikoku Pharma Usa, Inc. Transdermal methods and systems for the delivery of corticosteroid compounds
WO2009059277A1 (en) * 2007-11-02 2009-05-07 University Of South Florida Synergistic modulation of microglial activation by nicotine and thc
US20090317400A1 (en) * 2008-05-05 2009-12-24 Krzysztof Masternak Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof
NZ589883A (en) * 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
US20110130457A1 (en) * 2008-08-06 2011-06-02 University Of Louisville Research Foundation, Inc. Wax-Based Emulsion for the Treatment of Dry Eye Conditions
CA2733642A1 (en) * 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
MX2011006609A (es) * 2008-12-18 2011-06-30 Novartis Ag Sal de hemi-fumarato del acido 1-[4-[1-(4-ciclohexil-3-trifluoro-m etil-benciloxi-imino)-etil]-2-etil-bencil]-azetidin-3-carboxilico .
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
MX2011011729A (es) * 2009-05-05 2012-04-10 Novimmune Sa Anticuerpo anti il-17f y metodos de uso de los mismos.
EP2429503A1 (en) * 2009-05-13 2012-03-21 Protein Delivery Solutions, LLC Pharmaceutical system for trans-membrane delivery
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
JP5730914B2 (ja) * 2010-03-05 2015-06-10 ブラス・モンキー・インコーポレイテッドＢｒａｓｓ Ｍｏｎｋｅｙ，Ｉｎｃ． Ｗｅｂブラウザにおける双方向通信および内容制御のシステムおよび方法
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
CN103108886B (zh) * 2010-07-20 2016-08-24 赛法隆澳大利亚控股有限公司 抗il-23杂二聚体特异性抗体
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
WO2014113068A1 (en) * 2013-01-18 2014-07-24 Loma Linda University Compositions and methods for diagnosing and treating sepsis
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045475A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
US11162943B2 (en) 2017-05-31 2021-11-02 Prometheus Biosciences Inc. Methods for assessing mucosal healing in Crohn's disease patients
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
CO4810232A1 (es) 1997-07-25 1999-06-30 Schering Corp Citoquinas de mamiferos y sus secuencias codificadoras
AU2661199A (en) 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods
ATE474849T1 (de) * 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
WO2000009552A1 (en) 1998-08-14 2000-02-24 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
AR022890A1 (es) 1999-03-11 2002-09-04 Schering Corp Citoquinas mamiferas; reactivos relacionados y metodos
US6800460B1 (en) * 1999-03-11 2004-10-05 Schering Corporation Mammalian cytokine complexes
EP1179066A2 (en) 1999-05-19 2002-02-13 Incyte Genomics, Inc. Extracellular signaling molecules
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
DE60038304T3 (de) 1999-09-09 2017-04-06 Merck Sharp & Dohme Corp. Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
ES2307618T3 (es) 2000-05-10 2008-12-01 Schering Corporation Proteinas subunidades de receptores de cotocinas de mamiferos, reactivos y metodos relacionados.
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
BR0312708A (pt) * 2002-07-17 2005-04-26 Warner Lambert Co Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com celecoxib ou valdecoxib
CA2501786C (en) 2002-10-30 2015-02-17 Genentech, Inc. Inhibition of il-17 production
ES2367302T3 (es) 2002-12-23 2011-11-02 Schering Corporation Usos de la citoquina il-23 de mamífero; reactivos relacionados.
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
ES2330220T3 (es) * 2003-03-10 2009-12-07 Schering Corporation Usos de antagonistas de il-23; reactivos relacionados.
WO2005108616A1 (en) * 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment

Also Published As

Publication number Publication date
MY141215A (en) 2010-03-31
AR051444A1 (es) 2007-01-17
TWI370136B (en) 2012-08-11
US7807471B2 (en) 2010-10-05
PE20060694A1 (es) 2006-09-01
WO2006036745A3 (en) 2006-12-28
TW200626173A (en) 2006-08-01
US20080038831A1 (en) 2008-02-14
US20060067936A1 (en) 2006-03-30
US7252971B2 (en) 2007-08-07
WO2006036745A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
UY29128A1 (es) Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos
CR9265A (es) Anticuerpos anti-il-12, y epitopes, composiciones, metodos de obtencion y usos de los mismos
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
EA201070479A1 (ru) Человеческие антиамилоидные антитела, композиции, способы и их применение
HN2006016512A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
BRPI0921665A2 (pt) humanizado anti-il-6 anticorpos
CY1121252T1 (el) Anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
AR073088A1 (es) Anticuerpos anti-il-13 obtenidos mediante ingenieria composiciones metodos y usos
AR069681A1 (es) Moleculas de union al receptor ox40 humano
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
WO2006085961A3 (en) Anti-mcp-1 antibodies, compositions, methods and uses
WO2006124451A3 (en) Anti-il-13 antibodies, compositions, methods and uses
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
UY29509A1 (es) Anticuerpos anti-il-6, composiciones, métodos y usos
UY29552A1 (es) Anticuerpos anti-mcp-1, composiciones, métodos y usos
UY33043A (es) Proteinas de enlace de antigenos anti-orai 1 y usos de las mismas
GT200600212A (es) Anticuerpos anti-mcp-1, composiciones, metodos y usos